Suppr超能文献

NF-κB/miR-448 调控反馈环路在化疗诱导的乳腺癌细胞上皮-间充质转化中的作用。

Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells.

机构信息

Department of Pathology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

出版信息

Cell Death Differ. 2011 Jan;18(1):16-25. doi: 10.1038/cdd.2010.103. Epub 2010 Aug 27.

Abstract

The epithelial-mesenchymal transition (EMT) induced by chemotherapeutic agents promotes malignant tumor progression; however, the mechanism underlying the drug-induced EMT remains unclear. In this study, we reported that miR-448 is the most downregulated microRNA following chemotherapy. Suppression of miR-448 correlated with EMT induction in breast cancer in vitro and in vivo. With the use of chromatin immunoprecipitation-seq analysis, we demonstrated that miR-448 suppression induces EMT by directly targeting special AT-rich sequence-binding protein-1 (SATB1) mRNA, leading to elevated levels of amphiregulin and thereby, increasing epidermal growth factor receptor (EGFR)-mediated Twist1 expression, as well as nuclear factor κB (NF-κB) activation. On the other hand, we also found that the adriamycin-activated NF-κB directly binds the promoter of miR-448 suppressing its transcription, suggesting a positive feedback loop between NF-κB and miR-448. Furthermore, all patients who received cyclophosphamide (CP), epirubicin plus taxotere/CP, epirubicin plus 5-fluorouracil chemotherapy showed miR-448 suppression, an increased SATB1, Twist1 expression and acquisition of mesenchymal phenotypes. These findings reveal an underlying regulatory pathway, in which the autoregulation between NF-κB and miR-448 is important for restrain miR-448 suppression upon chemotherapy and may have a role in the regulation of chemotherapy-induced EMT. Disruption of the NF-κB-miR-448 feedback loop during clinical treatment may improve the chemotherapy response of human breast cancers in which EMT is a critical component.

摘要

上皮-间充质转化(EMT)被化疗药物诱导,促进恶性肿瘤进展;然而,药物诱导 EMT 的机制尚不清楚。在这项研究中,我们报道了 miR-448 是化疗后下调最明显的 microRNA。miR-448 的抑制与体外和体内乳腺癌的 EMT 诱导相关。通过染色质免疫沉淀-seq 分析,我们证明 miR-448 的抑制通过直接靶向特殊富含 AT 的序列结合蛋白-1(SATB1)mRNA 诱导 EMT,导致 Amphiregulin 水平升高,从而增加表皮生长因子受体(EGFR)介导的 Twist1 表达以及核因子 κB(NF-κB)的激活。另一方面,我们还发现阿霉素激活的 NF-κB 直接结合 miR-448 的启动子,抑制其转录,提示 NF-κB 和 miR-448 之间存在正反馈环。此外,所有接受环磷酰胺(CP)、表柔比星加紫杉醇/CP、表柔比星加 5-氟尿嘧啶化疗的患者均表现出 miR-448 抑制、SATB1、Twist1 表达增加和获得间充质表型。这些发现揭示了一个潜在的调控途径,其中 NF-κB 和 miR-448 之间的自动调节对于抑制化疗后 miR-448 的抑制很重要,并且可能在调节化疗诱导的 EMT 中发挥作用。在临床治疗过程中破坏 NF-κB-miR-448 反馈回路可能会改善 EMT 是关键组成部分的人类乳腺癌的化疗反应。

相似文献

引用本文的文献

3
Transglutaminase 2 in breast cancer metastasis and drug resistance.转谷氨酰胺酶2在乳腺癌转移和耐药性中的作用
Front Cell Dev Biol. 2024 Oct 31;12:1485258. doi: 10.3389/fcell.2024.1485258. eCollection 2024.
7
Epigenetic regulation in cancer.癌症中的表观遗传调控。
MedComm (2020). 2024 Feb 19;5(2):e495. doi: 10.1002/mco2.495. eCollection 2024 Feb.
8
Breast cancer: miRNAs monitoring chemoresistance and systemic therapy.乳腺癌:微小RNA监测化疗耐药性及全身治疗
Front Oncol. 2023 Jun 16;13:1155254. doi: 10.3389/fonc.2023.1155254. eCollection 2023.

本文引用的文献

3
SMAD proteins control DROSHA-mediated microRNA maturation.SMAD蛋白控制DROSHA介导的微小RNA成熟。
Nature. 2008 Jul 3;454(7200):56-61. doi: 10.1038/nature07086. Epub 2008 Jun 11.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验